293 related articles for article (PubMed ID: 37828588)
1. Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal.
Ando Y; Waddington-Cruz M; Sekijima Y; Koike H; Ueda M; Konishi H; Ishii T; Coelho T
Orphanet J Rare Dis; 2023 Oct; 18(1):323. PubMed ID: 37828588
[TBL] [Abstract][Full Text] [Related]
2. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.
Adams D; Ando Y; Beirão JM; Coelho T; Gertz MA; Gillmore JD; Hawkins PN; Lousada I; Suhr OB; Merlini G
J Neurol; 2021 Jun; 268(6):2109-2122. PubMed ID: 31907599
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies.
Ueda M; Sekijima Y; Koike H; Yamashita T; Yoshinaga T; Ishii T; Ando Y
J Neurol Sci; 2020 Jul; 414():116813. PubMed ID: 32353608
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.
Sekijima Y; Ueda M; Koike H; Misawa S; Ishii T; Ando Y
Orphanet J Rare Dis; 2018 Jan; 13(1):6. PubMed ID: 29343286
[TBL] [Abstract][Full Text] [Related]
5. Counseling Family Members and Monitoring for Evidence of Disease in Asymptomatic Carriers of Amyloid Transthyretin Cardiac Amyloidosis.
Barker N; Judge DP
Am J Cardiol; 2022 Dec; 185 Suppl 1():S43-S50. PubMed ID: 36216601
[TBL] [Abstract][Full Text] [Related]
6. Hereditary transthyretin amyloidosis overview.
Manganelli F; Fabrizi GM; Luigetti M; Mandich P; Mazzeo A; Pareyson D
Neurol Sci; 2022 Dec; 43(Suppl 2):595-604. PubMed ID: 33188616
[TBL] [Abstract][Full Text] [Related]
7. Origin of sporadic late-onset hereditary ATTR Val30Met amyloidosis in Japan.
Ueda M; Yamashita T; Misumi Y; Masuda T; Ando Y
Amyloid; 2018 Sep; 25(3):143-147. PubMed ID: 30486687
[TBL] [Abstract][Full Text] [Related]
8. A natural history analysis of asymptomatic
Coelho T; Conceição I; Waddington-Cruz M; Keohane D; Sultan MB; Chapman D; Amass L;
Amyloid; 2022 Dec; 29(4):228-236. PubMed ID: 35730447
[TBL] [Abstract][Full Text] [Related]
9. First Norwegian case of hereditary ATTR amyloidosis with a novel transthyretin variant.
Lyng CS; Gude E; Hodt A; Knudsen EC
Scand Cardiovasc J; 2023 Dec; 57(1):2174269. PubMed ID: 36734834
[TBL] [Abstract][Full Text] [Related]
10. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
[TBL] [Abstract][Full Text] [Related]
11. Practice of Hereditary ATTR Amyloidosis in Non-endemic Areas of Japan.
Matsushima M; Tarisawa M; Nomura T; Oshima Y; Yoshino M; Shibata Y; Wakita M; Shirai S; Iwata I; Yaguchi H; Yabe I
Intern Med; 2023 Jun; 62(11):1599-1602. PubMed ID: 36261369
[TBL] [Abstract][Full Text] [Related]
12. Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression.
Adams D; Algalarrondo V; Polydefkis M; Sarswat N; Slama MS; Nativi-Nicolau J
Orphanet J Rare Dis; 2021 Oct; 16(1):411. PubMed ID: 34602081
[TBL] [Abstract][Full Text] [Related]
13. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.
Carroll A; Dyck PJ; de Carvalho M; Kennerson M; Reilly MM; Kiernan MC; Vucic S
J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):668-678. PubMed ID: 35256455
[TBL] [Abstract][Full Text] [Related]
14. Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan.
Yamashita T; Ueda M; Misumi Y; Masuda T; Nomura T; Tasaki M; Takamatsu K; Sasada K; Obayashi K; Matsui H; Ando Y
J Neurol; 2018 Jan; 265(1):134-140. PubMed ID: 29177547
[TBL] [Abstract][Full Text] [Related]
15. Characterization and natural history of different phenotypes in hereditary transthyretin amyloidosis: 40-year experience at a single Italian referral centre.
Caponetti AG; Sguazzotti M; Accietto A; Saturi G; Ponziani A; Giovannetti A; Massa P; Ruotolo I; Sena G; Zaccaro A; Parisi V; Bonfiglioli R; Guaraldi P; Gagliardi C; Cortelli P; Galie N; Biagini E; Longhi S
Eur J Prev Cardiol; 2024 May; 31(7):866-876. PubMed ID: 38204330
[TBL] [Abstract][Full Text] [Related]
16. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis.
Coelho T; Maurer MS; Suhr OB
Curr Med Res Opin; 2013 Jan; 29(1):63-76. PubMed ID: 23193944
[TBL] [Abstract][Full Text] [Related]
17. Assessment of patients with hereditary transthyretin amyloidosis - understanding the impact of management and disease progression.
Conceição I; Coelho T; Rapezzi C; Parman Y; Obici L; Galán L; Rousseau A
Amyloid; 2019 Sep; 26(3):103-111. PubMed ID: 31339362
[TBL] [Abstract][Full Text] [Related]
18. [Clinical diversity, diagnosis and treatment of hereditary amyloid neuropathy].
Sekijima Y
Rinsho Shinkeigaku; 2014; 54(12):953-6. PubMed ID: 25672679
[TBL] [Abstract][Full Text] [Related]
19. Recommendations for the diagnosis and management of transthyretin amyloidosis with gastrointestinal manifestations.
Nakov R; Suhr OB; Ianiro G; Kupcinskas J; Segal JP; Dumitrascu DL; Heinrich H; Mikolasevic I; Stojkovic-Lalosevic M; Barbov I; Sarafov S; Tournev I; Nakov V; Wixner J
Eur J Gastroenterol Hepatol; 2021 May; 33(5):613-622. PubMed ID: 33394808
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
